Press Releases

Exclusive Global Maritime Partnership Team Prepares for Future

ALEXANDRIA, Va.--(BUSINESS WIRE)-- VSE Corporation's (Nasdaq GS: VSEC) GLOBAL Division (formerly BAV) announces a new, exclusive, and dynamic Naval Ship Transfer and Repair (N*STAR) team to expedite the transfer of former U.S. Navy ships and systems to foreign allies and provide comprehensive in-country follow-on technical support, including training, engineering services, industrial services, construction and logistics support.

N*STAR team members include some of the top industry leaders, such as Raytheon, Science Applications International Corporation (SAIC), Thales Naval, Inc., General Dynamics, Lockheed Martin, Computer Sciences Corporation (CSC), BAE SYSTEMS and American Systems Corporation.

Other members of the VSE team include: Propulsion Controls Engineering; George G. Sharp, Inc.; Gibbs & Cox, Inc.; Colonna's Shipyard, Inc.; McKean Defense Group, LLC; Phoenix Group of VA; Sullivan & Associates, Inc.; Atlantic Marine Florida, LLC; 3Phoenix, Inc.; The Columbia Group; Logistics Support, Incorporated; CDI Marine Co.; The GBS Group; The McHenry Management Group; and Orion Solutions, LLC.

VSE has been the lead firm performing ship transfer work for the Naval Sea Systems Command under the Foreign Military Sales ("FMS") Program since this function was initially outsourced in 1995. During that time, VSE has managed the successful transfer of 42 ships to 34 nations on six continents. The transfer services have included a large variety of ships/systems, from guided missile destroyers to floating dry docks. VSE is currently supporting the transfer of the ex-USNS Andrew J. Higgins to Chile at the Atlantic Marine shipyard in Mobile, Ala.

The extensive VSE-led support work includes complex follow-on technical support to host nations from construction/establishment of state-of-the-art, multimedia training facilities; coastal surveillance systems; industrial upgrade programs, including building facilities and procedures capable of supporting former U.S. Navy ships and systems; and engineering support for mission capability enhancements, including complex systems integration projects such as installation of modern combat systems upgrades (SM2 Block IIIA).

"By partnering with the most respected names in the defense business, we've built a powerful team for the future on a foundation of almost 15 years of proven past performance, positive client feedback and outstanding award fee scores," said VSE CEO/President/COO Maurice "Mo" Gauthier. "VSE's N*STAR team of exclusive tier one industry partners is testimony to our strength and reputation in the demanding FMS market. Each of our teammates chose the VSE N*STAR team because of strong ongoing working relationships with VSE and a clear-eyed assessment of VSE's performance and value to this market going forward."

Michael Hamerly, President of VSE's International Group, commented, "VSE has developed many unique and proprietary tools for FMS work including the automated condition report system, automated industrial project financial tracking, and Foreign Military Sales Lessons Learned database. This is an outstanding opportunity for every team member to take ship and system transfers to the next level of service excellence and we are now poised to enrich the program even further."

VSE International Group

International Group provides global engineering, industrial and logistics services for foreign military sales. GLOBAL Division provides assistance to the U.S. Navy in executing its Foreign Military Sales Program for surface ships sold, leased or granted to foreign countries by providing program management, engineering, technical support, and logistics services for ship reactivations, transfers, and follow-on support. For more information about International Group's services please see the VSE Corporation website at www.vsecorp.com or contact Donald Babcock at (703) 329-4683.

About VSE

VSE is Federal Services Company of choice for solving issues of global significance with integrity, agility and value. VSE marked its 50th year as a government contractor in January 2009 and is dedicated to making our clients successful by delivering talented people and innovative solutions for program management, logistics, engineering, IT services, construction program management and consulting. For additional information on VSE services and products, please see our web site at www.vsecorp.com or contact Randy Hollstein, Corporate Vice President of Sales and Marketing, at (703) 329-3206.

VSE encourages investors and others to review the detailed reporting and disclosures contained in VSE public filings with the Securities and Exchange Commission for further information and analysis of VSE's financial condition and results of operations. The public filings include additional discussion about the status of specific customer programs and contract awards, risks, revenue sources and funding, dependence on material customers, and management's discussion of short and long term business challenges and opportunities.

    Source: VSE Corporation

NEWARK, N.J.--(BUSINESS WIRE)-- Prudential Financial, Inc. (NYSE: PRU) will hold its New York conference for institutional investors and analysts on December 10, 2009. The day's schedule will commence with opening remarks at 8:30 a.m. and is expected to conclude at approximately 12:30 p.m. with lunch to follow. Breakfast will be served beginning at 7:30 a.m.

Presenters at this conference will include John Strangfeld, CEO and Chairman, and other members of the senior management team.

To register for this conference and obtain venue information, please e-mail your name, company name, phone number, and e-mail address to prudential@irnavigator.com prior to December 1, 2009.

The general public is invited to access a live webcast beginning at 8:30 a.m., on December 10 on the Investor Relations website at www.investor.prudential.com. A replay of the webcast will be available through December 24, 2009. For questions, please write to investor.relations@prudential.com.

Prudential Financial, Inc. (NYSE: PRU), a financial services leader with approximately $641 billion of assets under management as of September 30, 2009, has operations in the United States, Asia, Europe, and Latin America. Leveraging its heritage of life insurance and asset management expertise, Prudential is focused on helping approximately 50 million individual and institutional customers grow and protect their wealth. The company's well-known Rock symbol is an icon of strength, stability, expertise and innovation that has stood the test of time. Prudential's businesses offer a variety of products and services, including life insurance, annuities, retirement-related services, mutual funds, investment management, and real estate services. For more information, please visit http://www.news.prudential.com/.

    Source: Prudential Financial, Inc.

LAKEWOOD, Ohio--(BUSINESS WIRE)-- GrafTech International Holdings Inc.'s Engineered Solutions natural graphite business, a leading producer of electronic thermal management solutions under its eGRAF(R) brand name, has settled its litigation with JTProfound Technology Co. Ltd. and its principal, Jing-Wen Tzeng. The settlement includes entry of a Consent Judgment in favor of GrafTech, finding that GrafTech's five patents involved in the case are all valid and enforceable, and that three of the patents were infringed by the defendants. The judgment also provides for a permanent injunction barring the defendants from selling infringing natural graphite sheet products to third parties in the US for thermal dissipation applications without GrafTech's prior approval, as well as monetary damages.

The ability to effectively dissipate heat from heat-generating components without harming adjacent components is critical to the development of ever-smaller, thinner, and lighter electronic devices like cell phones, laptop computers, and flat panel televisions. GrafTech pioneered the use of sheets of compressed particles of exfoliated graphite to solve this problem and created the market for the use of this material for electronic thermal management. GrafTech has a portfolio of patents protecting this technology globally.

"GrafTech is committed to aggressively enforcing its intellectual property rights relating to technology that we invented, perfected, and commercialized," stated Brad Reis, GrafTech's Director of Intellectual Property. "We have a focused strategy to ensure that our intellectual property rights in the area of graphite thermal management products are respected."

GrafTech International's natural graphite business is one of the world's largest manufacturers and providers of high quality natural graphite products. We also manufacture thermal management, fuel cell and other natural graphite products for the electronics, transportation, and other markets. For additional information visit our website at www.graftech.com. Except for historical information, the matters contained or discussed in this release are forward-looking statements and are based on management's current expectations. Factors that could cause actual results to differ materially from those in the forward-looking statements include: our ability to effectively enforce our intellectual property rights, changes in the markets and demand for our products, competitive pressures, competing technologies, and changes in economic conditions. We have no obligation to update any of the information in this release.

    Source: GrafTech International Ltd.

STAMFORD, Conn.--(BUSINESS WIRE)-- Silgan Holdings Inc. (Nasdaq: SLGN), a leading supplier of consumer goods packaging products, announced today that its Board of Directors has declared a quarterly cash dividend on its common stock. The Board of Directors approved a $0.19 per share quarterly cash dividend, payable on December 15, 2009 to the holders of record of common stock of the Company on December 1, 2009.

Silgan Holdings is a leading manufacturer of consumer goods packaging products with annual net sales of approximately $3.1 billion in 2008. Silgan operates 66 manufacturing facilities in North and South America, Europe and Asia. In North America, Silgan is the largest supplier of metal containers for food products and a leading supplier of plastic containers for personal care products. In addition, Silgan is a leading worldwide supplier of metal, composite and plastic vacuum closures for food and beverage products.

    Source: Silgan Holdings Inc.

NEW YORK, Nov. 11 /PRNewswire-FirstCall/ -- Pulmo BioTech Inc. (OTC Bulletin Board: PLMO.OB; Frankfort Borse: PBO) has announced that early experimental results have indicated that its PulmoBind(TM) product candidate can be potentially used for the early detection and follow-up of many conditions that affect the physical and/or biological integrity of the Pulmonary Circulation. These early results, if confirmed by further experiments, would broaden the range of conditions that PulmoBind(TM) is able to diagnose.

"We are very pleased with these early results. To date, we have mainly concentrated on the use of PulmoBind(TM) as a diagnostic agent for Pulmonary Hypertension (PH) and Pulmonary Embolism (PE). While our work in these areas continues, early experimental results have indicated that PulmoBind(TM) could be used to diagnose a wide range of Pulmonary Vascular diseases associated with lung disorders, heart disease and connective tissue disease. For example, lung disorders associated with HIV, Cirrhosis and Shistosomiasis are all conditions that we believe could potentially be diagnosed using PulmoBind(TM). If our experimental results can be confirmed, then PulmoBind(TM) has great potential as a front-line test to either confirm or exclude disorders of the Pulmonary Circulation in patients who present with "shortness of breath". PulmoBind(TM) could also help in predicting outcomes in these patients and guiding their therapy." - Garry McCann, CEO Pulmo BioTech Inc.

About Pulmo BioTech Inc.

Pulmo BioTech Inc. specializes in the development and marketing of medical technology and research. Our proven strengths combine extensive commercial experience and academic credentials. The principal staff members are acknowledged experts in their specialized fields, and work with a broad range of investment institutions. Our mission is to utilize scientific imagination and drive, together with managerial and financial acumen, to bring innovative and profitable products to the marketplace to the benefit of all stockholders.

ISIN: US7458451074

CUSIP: 745845107

WKN: A0RDTZ

About PulmoScience Inc.

PulmoScience Inc. was established in 2006, and is currently developing a non-invasive Molecular Imaging technique for the diagnosis of Pulmonary Embolism, Pulmonary Hypertension and Lung Inflammatory diseases under the trade name PulmoBind(TM).

PulmoScience was conceived within the Montreal Heart Institute "MHI" (a world renowned hospital and educational facility). Jointly owned by MHI subsidiary Innovacor as the technical and operational partner, Dr. Jocelyn Dupuis (the scientific director and originator of the PulmoBind(TM) Molecular Imaging technology), and by Pulmo BioTech Inc. as the funding partner, PulmoScience Inc. aims to develop this unique and exciting technology, to fund necessary trials, and to bring the products to market.

PulmoScience believes that the market for its product candidates is worth in excess of $500 million per annum and that, provided Regulatory Approval is achieved, the safety and efficacy of its products could allow it to dominate that market.

About PulmoBind(TM)

PulmoBind(TM) uses an intravenously delivered radionuclide tagged molecule which specifically bonds to the inner walls of the circulatory system in the lungs, and by the use of an external Gamma Camera allows an image of the integrity of the blood vessels throughout the lungs to be seen by a diagnostic clinician. PulmoScience is currently undertaking Regulatory Approval for Phase I Human Trials, and while subsequent results from additional tests might not corroborate the current results, PulmoScience believes that PulmoBind(TM) has the potential to dominate the market for the diagnosis of Pulmonary Embolism. In particular, this belief is driven by PulmoScience's expectations of the improved safety and efficacy that PulmoBind(TM) will offer when compared to the current incumbent nuclear medicine based technology for the diagnosis of Pulmonary Embolism. In addition, early indications are that PulmoBind(TM) could be highly effective in the early stage diagnosis of Pulmonary Hypertension, a condition for which there is no current front line diagnostic test. The addressable market for the product candidates being developed by PulmoScience is believed by the company to be worth in excess of $500 million per annum.

Further Information

For further information regarding Pulmo BioTech Inc. or PulmoScience, please visit www.pulmobiotech.com.

Forward-Looking Statements

Forward-looking statements contained in this and other written and oral reports are made based on known events and circumstances at the time of release, and as such, are subject in the future to unforeseen uncertainties and risks. All statements regarding future performance, earnings projections, regulatory approval, events or developments are forward-looking statements. It is possible that the future performance of the company may differ materially from current expectations, depending on economic conditions and the uncertainty of regulatory approval. A change in economic conditions may have a particularly volatile effect on results. Among the other factors which may affect future performance are: competitive market conditions and resulting effects on sales and pricing; increases in raw-material costs that cannot be recovered in product pricing; and global economic factors, including difficulties entering new markets and general economic conditions such as inflation, interest rates and credit availability. The company makes these statements as of the date of this disclosure, and undertakes no obligation to update them.

SOURCE Pulmo BioTech Inc.